Polymer therapeutics—polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities*

Welsh School of Pharmacy, Centre for Polymer Therapeutics, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK, University of Mainz, Institute of Organic Chemistry, Duesbergweg 10-14 D-55099, Mainz, Germany, and Vascular Biology Program, Department of Surgery, Children’s Hospital Boston and Harvard Medical School, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, MA 02115, USA

[1]  H. Ringsdorf,et al.  Polymeric Antitumor Agents on a Molecular and on a Cellular Level , 1981 .

[2]  R. Duncan.  N-(2-Hydroxypropyl) methacrylamide Copolymer , 2005 .

[3]  E. Wagner.  Strategies to Improve DNA Polyplexes for in Vivo Gene Transfer: Will “Artificial Viruses” Be the Answer? , 2004, Pharmaceutical Research.

[4]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[5]  Kazunori Kataoka,et al.  Block copolymer micelles for delivery of gene and related compounds. , 2002, Advanced drug delivery reviews.

[6]  H. Ringsdorf.  Structure and properties of pharmacologically active polymers , 1975 .

[7]  C. Carraher,et al.  Bioactive Polymeric Systems , 1985 .

[8]  H. Ringsdorf,et al.  Polymeric monolayers and liposomes as models for biomembranes , 1985 .

[9]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[10]  H. Ringsdorf,et al.  Polymeric monolayers and liposomes as models for biomembranes. How to bridge the gap between polymer science and membrane biology , 1984 .

[11]  J. Davies,et al.  Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 , 2004, Nature Medicine.

[12]  Jean-François Gohy,et al.  Block copolymer micelles , 2005 .

[13]  H. Morawetz.  Polymers: The Origins and Growth of a Science , 1985 .

[14]  J. Kopeček,et al.  Soluble synthetic polymers as potential drug carriers , 1984 .

[15]  D. Breslow.  Biologically Active Synthetic Polymers , 1976 .

[16]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[17]  H. Ringsdorf.  Hermann Staudinger and the future of polymer research jubilees-beloved occasions for cultural piety. , 2004, Angewandte Chemie.

[18]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1953, Nature.

[19]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[20]  L. Seymour,et al.  Review : Synthetic Polymers with Intrinsic Anticancer Activity , 1991 .

[21]  P. Tulkens,et al.  Commentary. Lysosomotropic agents. , 1974, Biochemical pharmacology.

[22]  F. Davis.  The origin of pegnology. , 2002, Advanced Drug Delivery Reviews.

[23]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[24]  W. Regelson.  Review: Advances in Intraperitoneal (Intracavitary) Administration of Synthetic Polymers for Immunotherapy and Chemotherapy , 1986 .

[25]  Horst Jatzkewitz,et al.  An ein kolloidales Blutplasma-Ersatzmittel (Polyvinylpyrrolidon) gebundenes Peptamin (Glycyl-L-leucyl-mezcalin) als neuartige Depotform für biologisch aktive primäre Amine (Mezcalin) , 1955 .

[26]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.